|
Company Report
|
Optimizing Partnerships with Contract Organizations
Optimizing Partnerships with Contract Organizations report provides a comprehensive review of pharmaceutical outsourcing partnerships and identifies expected changes in relationship dynamics over the next five years.
|
|
Read more...
|
|
|
Market Report
|
Lifestyle Drugs Market Outlook: Key Indications, Epidemiology, and Emergent Drugs
The market for lifestyle drugs has become one of the most dynamic and commercially attractive sectors in the pharmaceutical industry.
|
|
Read more...
|
|
|
Product Report
|
Nanotechnology: Revolutionizing R&D to develop smarter therapeutics and diagnostics
‘Nanotechnology’ is a new report published by Business Insights that provides a comprehensive review of nanotechnology and it’s role in the development of next-generation nanomedicines.
|
|
Read more...
|
|
|
Market Report
|
The Cancer Market Outlook to 2012
The Cancer Market Outlook to 2012 is a new report published by Business Insights that provides comprehensive coverage of the major markets in the global cancer area, incorporating a detailed epidemiological analysis of the nine major indications and key factors impacting their prevalence.
|
|
Read more...
|
|
|
Market Report
|
Innovations in Bioinformatics: Emerging tools for drug discovery and development
‘Innovations in Bioinformatics’ is a new report published by Business Insights that provides a detailed analysis of bioinformatic developments and applications. This report examines the bioinformatic tools used to manage high-throughput data from omic technologies, systems biology modelling and biomarker discovery.
|
|
Read more...
|
|
|
Market Report
|
Launching Combination Products: Brand extension and franchise development strategies
Launching Combination Products is a new report published by Business Insights that provides detailed strategic guidance for the preparation and successful execution of combination product launches. This report performs a comprehensive examination of current competitive pressures, best practices and future developments in key therapeutic areas including cardiovascular, respiratory, HIV and women’s health.
|
|
Read more...
|
|
|
Market Report
|
The Cardiovascular Disorders Market Outlook to 2012
The Cardiovascular Disorders Market Outlook to 2012 is a new report published by Business Insights that provides comprehensive coverage of every class of drugs across all major cardiovascular indications.
|
|
Read more...
|
|
|
Product Report
|
The Future of Targeted Therapeutics: Key technologies, new therapy area applications
In recent years, the maximization of blockbuster revenues has been compromised by generic price erosion and a decline in new drug approvals. Large pharmaceutical companies are coming under pressure to explore new R&D strategies and implement more cost-effective sourcing methods for innovative new molecules.
|
|
Read more...
|
|
|
Market Report
|
Drug Approval Trends at the FDA and EMEA: Process improvements, heightened scrutiny and response
Drug approvals in the US and Europe have become subject to approval delays, rising requests for further clinical data, and greater chances of rejection. Regulators are currently attempting to reconfigure review processes in order to minimize delays in recognition of the potential mass benefit of new applications.
|
|
Read more...
|
|
|
Product Report
|
Convergence of Biomarkers and Diagnostics: Therapy area analyses, key products and future trends
In recent years, there have been concerted efforts to enhance the precision of disease diagnosis and monitoring as the hetrogeneity of conditions becomes increasingly understood. Targeting broad patient populations in a ‘one-pill-fits-all’ approach has begun to attract criticism, with the average efficacy of such drugs being estimated at 50% or less.
|
|
Read more...
|
|
|
Market Report
|
Sepsis - The Critical Care Community Gains Critical Mass
 The Critical Care Community is currently at its most organized, and motivated, and on a mission to improve outcomes in sepsis. This is driving a rigorous assessment of care strategies which is gathering speed and showing results. This will yield many opportunities for developing products, but current interventions' roles will change, with impacts on how they are measured, used and valued.
|
|
Read more...
|
|
|
Market Report
|
Portable Inhaler Devices - Key tools to differentiate brands and survive gener
An overview of the market for portable inhalers, looking at market shares, usefulness as tools for franchise protection and -expansion. Patient- and physician preferences are being analyzed as well as suitablility of molecules and inhaler types.
|
|
Read more...
|
|
|
Market Report
|
ADHD - Immature adult market continues to offer greatest commercial
The ADHD market is currently valued at $3.85 billion and is set to increase over the next 10 years at a CAGR of 1.2%. Despite the continuing dominance of stimulant drugs, the 2002 launch of Strattera, the first non-stimulant treatment for ADHD, and the 2006 launch of Daytrana have served to open up the market, giving patients and physicians a greater choice of treatment options.
|
|
Read more...
|
|
|
Market Report
|
 Breast Cancer - Recent approvals increase pressure on pipeline candidates
Incidence of breast cancer in the seven major markets will total 455,000 in 2008, while 115,000 women will die from the disease. Despite advances in treatment over the past decade, significant unmet needs remain. This level of demand and the large patient potential make breast cancer a relatively attractive indication for drug developers.
|
|
Read more...
|
|
|
Market Report
|
Heart Failure - When drugs do not work
Advanced heart failure is a growing issue. Existing pharmacological strategies increase the survival rates of acute heart failure patients, providing a growing source of patients with advanced disease. In view of long waiting lists for heart transplantation and the growing lack of donors, cardiac resynchronization and mechanical circulatory support devices have demonstrated promising results.
|
|
Read more...
|
|
|
Market Report
|
Non-Small Cell Lung Cancer - Pipeline set to offer only modest improvements
Non-small cell lung cancer accounts for about 80% of all lung cancers. In 2008, the incidence of NSCLC is forecast to exceed 367,000 new cases in the seven major pharmaceutical markets. The high incidence of the disease and the large unmet need make NSCLC an attractive market for new drug development.
|
|
Read more...
|
|
|
Market Report
|
HRT for Menopausal Symptoms – A new class restores an old market
In 2007, the market value of HRT for menopausal symptoms saw its first upturn since the Women’s Health initiative (WHI) study results in 2002; highly publicized findings which linked HRT to cancer and cardiovascular safety risks. The recent growth of the market is due in part to the increasing price of HRT products but can only be sustained by a similar increase in volume sales.
|
|
Read more...
|
|
|
Product Report
|
Nosocomial Vaccines - Minefield or Goldmine?
As the reimbursement status for the cost of hospital-acquired infections is under pressure by payors, interest in preventing these complications at the outset is growing.Nosocomial vaccines offer one route of prevention. This report assesses the clinical pipeline candidates five key nosocomial pathogens and their potential market environment including target population size estimates.
|
|
Read more...
|
|
Farmavita.Net Journal 
